资讯

Targeted Oncology22 小时
Taletrectinib Data Published as FDA Weighs Approval for ROS1+ NSCLC
The FDA is evaluating a new drug application for taletrectinib in patients with ROS1 fusion–positive non–small cell lung ...
Science Daily12 天
Researchers identify mutations that can lead to resistance to some chemotherapies
Investigators have uncovered how resistance to chemotherapies may occur in some cancers. Researchers focused on a pathway that harnesses reactive oxygen species (ROS) to kill cancer cells. The study ...
The Print on MSN11 天
PGIMER report bats for new-age targeted lung cancer therapies to be included in AB-PMJAY
Report commissioned by govt analysed cost-effectiveness of 2 medicines, comparing them to to chemo in patients with newly ...
pharmaphorum1 年
BMS gets US approval for ROS1 lung cancer drug Augtyro
has been cleared for patients with ROS1-positive non-small-cell lung cancer (NSCLC) on the back of overall response rate (ORR) data from the phase 1/2 TRIDENT-1 study after a priority review by ...
Nuvation Bio launches EAP for lung cancer drug taletrectinib
The program targets individuals with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have exhausted other treatment options. The EAP, authorized by the U.S ...